Aristotle University Of Thessaloniki (AUTH)
Ασφάλεια και αποτελεσματικότητα της νέας φαρμακοτεχνικής μορφής της χηλικής ουσίας δεφερασιρόξης στην αποσιδήρωση παιδιατρικών ασθενών με μεταγγισιοεξαρτώμενα θαλασσαιμικά σύνδρομα
Abstract
dc:descriptionThe current study was designed, aiming to assess safety and efficacy of the new DFX FCT formulation in pediatric patients with transfusion-dependent thalassemia. In total, 25 pediatric patients followed at the Thalassemic Unit for Children and Adolescents of 1st Pediatric Department, Aristotle University of Thessaloniki, were enrolled. Mean patient age was 13 years. Median ferritin value showed no statistically significant change at the end of study, though, mean initial DFX FCT dose had to be significantly increased in order to achieve the desired control of iron overload till study end. Mean serum creatinine (sCr ) value and estimated GFR presented no significant change after 12-month DFX FCT therapy. Five (20%) patients showed a sCr increase of >33% during follow up compared to baseline values, and in one patient DFX discontinuation was deemed necessary. Furthermore, at study entry 9 (36%) patients presented with calcinuria. Mean spot urinary protein and calcium: creatinine ratio demonstrated no significant change at study end. Increase in spot urinary protein was reported in 12 (48%) patients, with one patient presenting a consistently abnormal value. A calcium: creatinine ratio increase was reported in 24 (96%) patients, out of which 15 (60%) showed a consistently abnormal value. Finally, renal ultrasound showed new imaging signs of nephrolithiasis in 2 (8%) patients at the end of the study. As for liver function, mean transaminases, bilirubin, as well as alkaline phosphatase values presented no significant change at the end of the study. At some point during the follow up, though, elevation of transaminases was reported in 14 (56%) patients and in 3 out of them DFX FCT was discontinued due to consistently abnormal liver enzyme. All patients presenting persistent transaminasemia belonged to the 2–6‐year group. Evaluation of body iron with MRI was performed in 19 (76%) patients. Mean cardiac MRI showed significant increase at study end, while mean LIC remained stable. Pure tone audiometry revealed a mild hearing loss in one (4%) patient at study end, while fundoscopy showed diffuse retinal pigmentation in another (4%) patient. Finally, with regards to other drug‐related adverse events, 5 (20%) cases were reported overall, including diarrhea, nausea, vomiting and skin rash. In all cases adverse events presented early in the course of the study and resolved quickly without intervention. In total, 21 (84%) patients completed the study, whereas 4 (16%) patients were switched to another chelator because of adverse events. No patient in the 2–6‐year group completed the study. In conclusion, study results confirmed DFX FCT safety in children >6 years old with transfusion-dependent thalassemic syndromes. However, DFX FCT demonstrated adverse events that limited its administration in younger age group. Furthermore, in comparison with previous studies, smaller percentage of pediatric patients presented with renal dysfunction. The vast majority, though, showed tubular dysfunction. With regards to efficacy, study results confirmed the preventive role of DFX FCT in iron loading of liver and heart, however, higher doses than generally recommended were required in order to ensure adequate chelation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Adramerina, Alkistis
- Αδραμερινά, Άλκηστις
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54207